Exhibit 99.1
|
|
www.CellTherapeutics.com |
Cell Therapeutics Reports Second Quarter 2013 Financial Results
- Conference call scheduled today at 4:30 p.m. Eastern time -
SEATTLE, July 31, 2013 - Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the second quarter and six months ended June 30, 2013.
“The second quarter was highlighted by the substantial progress we made in our reimbursement discussions for PIXUVRI® (pixantrone) in Europe, specifically in the UK and Italy,” said James Bianco, M.D., President and CEO of CTI. “In particular, we look forward to our planned launch of PIXUVRI in Italy, where AIFA granted market access to bring this new approved therapy to patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed 2 or 3 prior regimens. In addition, PERSIST-1, our randomized Phase 3 clinical trial designed to evaluate the safety and efficacy of pacritinib compared to best available therapy, excluding JAK inhibitors, continues to enroll patients with myelofibrosis. A second planned Phase 3 trial is on track to initiate later this year.”
Second Quarter 2013 and Recent Highlights
| PIXUVRI® (pixantrone) Commercial: |
Reimbursement Progress in Top European Markets |
| • | Received notice in July that market access in Italy was granted by the Italian Medicines Agency (AIFA) for PIXUVRI as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell NHL (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy). |
| • | Received notice in July that the UK’s Department of Health approved CTI’s patient access scheme relating to PIXUVRI. An independent appraisal committee of the National Institute for Health and Clinical Excellence (NICE) is scheduled to consider the new evidence on the cost effectiveness of PIXVURI at its meeting in September 2013. |
| • | Announced in May that Germany’s Federal Joint Committee (G-BA) reported that additional benefit could not be determined for PIXUVRI versus the comparator therapies assigned by the G-BA under Germany’s AMNOG law. The determination reflected the absence of a comparator under AMNOG law specifically for this stage of aggressive NHL because prior to the approval of PIXUVRI in the European Union |
| 3101 Western Ave. #600 Seattle, WA 98121 |
T 206.282.7100 F 206.284.6206 |
Page 2 of 5
| (E.U.), there was no therapy specifically approved for this stage of disease. The G-BA also decided that the prescribability for PIXUVRI should be limited to hematologists and oncologists. CTI is currently negotiating pricing with the GKV-SV, the Federal Association of Statutory Health Insurance Funds. |
Research and Development: New Data Presentation on Pacritinib’s Safety Profile
| • | Reported results from pooled integrated safety analysis from four Phase 1 and 2 clinical studies that demonstrated the safety, tolerability and persistence of pacritinib, CTI’s novel, oral JAK2/FLT3 inhibitor, in patients with myelofibrosis at the European Hematology Association Congress. |
| • | Reported on the publication of a comprehensive article summarizing preclinical and clinical data for pacritinib, authored by Srdan Verstovsek, M.D., Ph.D., et al., in the journal Drugs of the Future 2013. |
Corporate: Added to Russell Indices and Established Leadership for SAB
| • | Added to Russell Investments’ Russell 3000® and Russell Global indices. |
| • | Named distinguished cancer investigator, Daniel Von Hoff, M.D., F.A.C.P., as Chairman and to lead formation of CTI’s Scientific Advisory Board (SAB). |
Second Quarter 2013 Financial Results
Total revenues for the second quarter and the six months ended June 30, 2013 were $0.3 million and $1.4 million, respectively. The revenues were solely attributable to net product sales of PIXUVRI. CTI sells PIXUVRI directly to health care providers and through a limited number of wholesale distributors in the E.U. CTI records product sales upon receipt of the product by the health care provider or distributor, net of estimated distributor discounts, government-mandated discounts and rebates, and estimated product returns. Any future revenues are dependent on market acceptance of PIXUVRI, the reimbursement decisions made by governmental authorities in each country where PIXUVRI is available for sale and other factors.
Loss from operations for the second quarter of 2013 was $17.9 million, compared to $49.4 million for the same period in 2012. For the first six months of 2013, loss from operations was $36.3 million compared to $67.5 million for the same period in 2012. The amount recorded for the three and six months ended June 30, 2012 included a $29.1 million expense for acquired in-process research and development related to the acquisition of pacritinib from S*BIO Pte Ltd. Non-cash, share-based compensation expense for the second quarter and first six months of 2013 was $2.0 million and $4.4 million, respectively, compared to $3.1 million and $5.1 million for the same periods in 2012.
The net loss for the second quarter of 2013 was $18.0 million, or ($0.17) per share, compared to $58.6 million, or ($1.38) per share, for the same period in 2012. For the first six months of 2013, net loss was $37.4 million, or ($0.35) per share, compared to $76.0 million, or ($1.83), per share for the same period in 2012.
| 3101 Western Ave. #600 Seattle, WA 98121 |
T 206.282.7100 F 206.284.6206 |
Page 3 of 5
As of June 30, 2013, CTI’s cash and cash equivalents totaled $28.6 million.
Financial Guidance for 2013
CTI reaffirms prior financial guidance that, for 2013, loss from operations excluding non-cash, share-based compensation expense, which is a non-GAAP measure, is expected to be approximately $60 to $65 million. Year-to-date for the six month period ended June 30, 2013, loss from operations, excluding non-cash share-based compensation expense, which is a non-GAAP measure, was $31.9 million. For more information regarding CTI’s use of these non-GAAP measures and a reconciliation of non-GAAP loss from operations excluding non-cash share-based compensation expense to loss from operations for the six months ended June 30, 2013, please refer to the section below entitled “Non-GAAP Financial Measures”.
Actual financial results for 2013 will vary based upon many factors, including the degree of market acceptance and determination of reimbursement rates for PIXUVRI in the E.U., the rate of patient enrollment in pacritinib clinical trials that are ongoing and planned for initiation in 2013 and other factors described in our filings with the SEC.
Conference Call Information
CTI management will host a conference call to review its second quarter 2013 financial results and provide an update on business activities. The event will be held today at 1:30 p.m. PDT / 4:30 p.m. EDT/ 10:30 p.m. CET. Participants can access the call at 1-877-941-6010 (domestic) or +1 480- 629-9643 (international). To access the live audio webcast or the subsequent archived recording, visit CTI’s website, www.celltherapeutics.com. Webcast and telephone replays of the conference call will be available at approximately two hours after completion of the call. Callers can access the replay by dialing 1-800-406-7325 (domestic) or +1 303-590-3030 (international). The access code for the replay is 4632014#. The telephone replay will be available until Wednesday, August 7, 2013.
About Cell Therapeutics, Inc.
Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit www.CellTherapeutics.com.
Non-GAAP Financial Measures
CTI has provided in this press release the historical financial measure of loss from operations, excluding share-based compensation expense, which is a non-GAAP measure, for the six months ended June 30, 2013, and the financial projection of loss from operations, excluding share-based compensation expense, which is a non-GAAP measure, for the 2013 fiscal year. Due to varying available valuation methodologies, subjective assumptions and the different
| 3101 Western Ave. #600 Seattle, WA 98121 |
T 206.282.7100 F 206.284.6206 |
Page 4 of 5
GAAP accounting treatment of different award types that companies can use under ASC Topic 718, CTI’s management believes that providing a non-GAAP financial measure that excludes share-based compensation can enhance management’s and investors’ comparison of CTI’s operating results over different periods of time as compared to the operating results of other companies.
Our use of a non-GAAP financial measure has limitations and should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Our reported non-GAAP loss from operations results in the exclusion of a recurring expense, since share-based compensation will continue to be a significant recurring expense in CTI’s business. Second, our methodology for calculating non-GAAP loss from operations, which only excludes the component of share-based compensation, may differ from the methodology our peer companies utilize to the extent they report non-GAAP loss from operations or similarly titled measures and accordingly may not necessarily be comparable to similarly titled measures of other companies. Investors are urged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of CTI’s non-GAAP financial measures to their most directly comparable GAAP measures has been provided in the financial statement tables included below in this press release.
CTI has not included a reconciliation of our projected non-GAAP amount to a projected GAAP loss from operations because the calculation of the excluded share-based compensation would require information that is presently uncertain, such as the future level of additional equity awards that will be granted to meet CTI’s compensation philosophy and objectives after taking into account the economic climate at the time of grant. In addition, the calculation is largely based on the price of CTI’s stock at the time of the specific grants (as required under ASC Topic 718), which price is variable and therefore unknowable until the grant is made. Because of the contingent nature of such factors, the specific adjustment for future share-based compensation cannot be forecast with accuracy.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI’s securities. Such statements include, but are not limited to, statements regarding CTI’s expectations with respect to the development of CTI and its product and product candidate portfolio, the anticipated availability of PIXUVRI in Italy, the enrollment for and timing of the second planned Phase 3 trial of pacritinib, NICE’s expected consideration of the new evidence on the cost effectiveness of PIXUVRI at its meeting scheduled to be held in September 2013 and CTI’s financial guidance for 2013. Risks that contribute to the uncertain nature of the forward-looking statements include, among others, risks associated with the biopharmaceutical industry in general and with CTI and its product and product candidate portfolio in particular including, among others, risks associated with the following: that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials; that CTI cannot predict or guarantee the outcome of preclinical and clinical studies; that CTI may not obtain reimbursement for PIXUVRI in certain markets in the E.U. as planned or at all; that the conditional marketing authorization for PIXUVRI may not be
| 3101 Western Ave. #600 Seattle, WA 98121 |
T 206.282.7100 F 206.284.6206 |
Page 5 of 5
renewed or may be subject to additional conditions; that the second Phase 3 clinical trial of pacritinib will not occur as planned or at all; that CTI may not obtain favorable determinations by other regulatory, patent and administrative governmental authorities; that CTI may experience delays in the commencement of preclinical and clinical studies; risks related to the costs of developing, producing and selling PIXUVRI, pacritinib, and CTI’s other product candidates; and other risks, including, without limitation, competitive factors, technological developments, costs of developing, producing and selling PIXUVRI, that CTI’s operating expenses continue to exceed its net revenues, that CTI may not be able to sustain its current cost controls or further reduce its operating expenses, that CTI’s average net operating burn rate may increase, that CTI will continue to need to raise capital to fund its operating expenses, but may not be able to raise sufficient amounts to fund its continued operation, as well as other risks listed or described from time to time in CTI’s most recent filings with the Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K. Except as required by law, CTI does not intend to update any of the statements in this press release upon further developments.
PIXUVRI is a registered trademark of Cell Therapeutics, Inc.
Source: Cell Therapeutics, Inc.
###
Contacts:
Monique Greer
+1 206.272.4343
mgreer@ctiseattle.com
Ed Bell
+1 206.282.7100
ebell@ctiseattle.com
In Europe
CTI Life Sciences Limited, Milan Branch
Laura Villa
+39 02 89659706
lvilla@cti-lifesciences.com
CTI_EUInvestors@CTI-Lifesciences.com
| 3101 Western Ave. #600 Seattle, WA 98121 |
T 206.282.7100 F 206.284.6206 |
Cell Therapeutics, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except for per share amounts)
(unaudited)
| Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
| 2013 | 2012 | 2013 | 2012 | |||||||||||||
| Revenues: |
||||||||||||||||
| Product sales, net |
$ | 306 | $ | — | $ | 1,432 | $ | — | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total revenues |
306 | — | 1,432 | — | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Operating costs and expenses: |
||||||||||||||||
| Cost of product sold |
36 | — | 91 | — | ||||||||||||
| Research and development |
8,020 | 8,959 | 16,375 | 17,129 | ||||||||||||
| Selling, general and administrative |
10,102 | 11,333 | 21,245 | 21,261 | ||||||||||||
| Acquired in-process research and development |
— | 29,108 | — | 29,108 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating costs and expenses |
18,158 | 49,400 | 37,711 | 67,498 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss from operations |
(17,852 | ) | (49,400 | ) | (36,279 | ) | (67,498 | ) | ||||||||
| Other income (expense): |
||||||||||||||||
| Investment and other income (expense), net |
107 | (99 | ) | (260 | ) | 91 | ||||||||||
| Interest expense |
(316 | ) | (3 | ) | (364 | ) | (8 | ) | ||||||||
| Amortization of debt discount and issuance costs |
(164 | ) | — | (187 | ) | — | ||||||||||
| Foreign exchange gain (loss) |
5 | (696 | ) | (746 | ) | (312 | ) | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss before noncontrolling interest |
(18,220 | ) | (50,198 | ) | (37,836 | ) | (67,727 | ) | ||||||||
| Noncontrolling interest |
209 | 60 | 441 | 143 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss attributable to CTI |
(18,011 | ) | (50,138 | ) | (37,395 | ) | (67,584 | ) | ||||||||
| Deemed dividends on preferred stock |
— | (8,458 | ) | — | (8,458 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss attributable to CTI common shareholders |
$ | (18,011 | ) | $ | (58,596 | ) | $ | (37,395 | ) | $ | (76,042 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Basic and diluted net loss per common share |
$ | (0.17 | ) | $ | (1.38 | ) | $ | (0.35 | ) | $ | (1.83 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Shares used in calculation of basic and diluted net loss per common share |
107,727 | 42,532 | 107,215 | 41,662 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Balance Sheet Data (unaudited): |
||||||||||||||||
| (amounts in thousands) | ||||||||||||||||
| June 30, 2013 |
December 31, 2012 |
|||||||||||||||
| Cash and cash equivalents |
$ | 28,568 | $ | 50,436 | ||||||||||||
| Working capital |
13,033 | 37,644 | ||||||||||||||
| Total assets |
49,232 | 73,713 | ||||||||||||||
| Current portion of long-term debt |
471 | — | ||||||||||||||
| Long-term debt, less current portion |
7,733 | — | ||||||||||||||
| Total shareholders’ equity (deficit) |
(357 | ) | 32,944 | |||||||||||||
Non-GAAP Reconciliation
(In thousands)
(unaudited)
| Six Months Ended June 30, |
||||
| 2013 | ||||
| As reported - loss from operations (GAAP) |
$ | (36,279 | ) | |
| As reported - share-based compensation expense (GAAP) |
$ | 4,396 | ||
|
|
|
|||
| As adjusted - loss from operations (Non-GAAP) |
$ |
(31,883 |
) | |
|
|
|
|||